Articles from this edition:
Latest articles
COVID-19 and key changes one year on
One year on from the first confirmed case of COVID-19 in the UK, Oli Hudson, Content Director at Wilmington Healthcare, takes a look at...
FDA approves Roche’s Actemra/RoActemra for interstitial lung disease
Roche has announced that the U.S. Food and Drug Administration (FDA) has approved Actemra®/RoActemra® (tocilizumab) subcutaneous injection for slowing the rate of decline in...
Pre-clinical work completed for novel COVID-19 immunotherapy
ISA Pharmaceuticals has announced that it has completed pre-clinical work for ISA106, a novel COVID-19 immunotherapy and is planning clinical trials. A phase 1...
Popular articles
New Normal, New Thinking: Life Post COVID-19
New thinking will be required to adapt to the new normal life post COVID-19. I hate to start this article on a negative note, but...
Study shows anti-parasitic drug ivermectin kills coronavirus within 48 hours
A collaborative study led by the Monash Biomedicine Discovery Institute (BDI) with the Peter Doherty Institute of Infection and Immunity (Doherty Institute), a joint...
Nasal spray to protect against COVID-19 is ready for use in humans
A nasal spray to provide protection against the COVID-19 virus has been formulated by researchers at the University of Birmingham, UK, using compounds already...
FDA approves Roche’s Actemra/RoActemra for interstitial lung disease
Roche has announced that the U.S. Food and Drug Administration (FDA) has approved Actemra®/RoActemra® (tocilizumab) subcutaneous injection for slowing the rate of decline in...
COVID-19 and key changes one year on
One year on from the first confirmed case of COVID-19 in the UK, Oli Hudson, Content Director at Wilmington Healthcare, takes a look at...